A Study of L-735,524 in HIV-Positive Children and Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00002351
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
Information provided by:
NIH AIDS Clinical Trials Information Service

November 2, 1999
August 31, 2001
June 24, 2005
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
A Study of L-735,524 in HIV-Positive Children and Adolescents
An Open-Labeled, Multiple Dose, Multicenter Study to Investigate the Safety, Tolerability, and Plasma Concentration Profile of L-735,524 Capsules in HIV-Seropositive Older Children and Adolescent Patients
To evaluate the safety, tolerability, and plasma concentration profiles of indinavir sulfate ( MK-639; Crixivan ) in HIV-seropositive older children and adolescents. To compare the plasma concentration profile after the initial dose with data from a historical group of adults. To obtain preliminary data on antiviral activity of MK-639.
Patients receive MK-639 for 14 and one-third days. Repeat plasma samples are collected up to 8 hours following the first and last dose. Urine samples are collected on days 1 and 5.
Phase 1
Primary Purpose: Treatment
HIV Infections
Drug: Indinavir sulfate
Not Provided
Mueller BU, Smith S, Sleasman J, Nelson RP Jr, Meyer C, Deutsch P, Zwerski S, Mistry G, Sei S, Wood L, Zeichner S, Brouwers P, Jarosinski P, Lewis L, Pizzo PA. A phase I/II study of the protease inhibitor indinavir (MK-0639) in children with HIV infection. Int Conf AIDS. 1996 Jul 7-12;11(Program Supplement):37 (abstract no WeB554)

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
Not Provided
Not Provided

Inclusion Criteria

Patients must have:

  • HIV positivity.
  • No active opportunistic infection within the past 30 days, other than superficial candidiasis of the oral cavity or vagina.
  • Body surface area at least 1.0 sqm.
  • Consent of parent or guardian.

Prior Medication:


  • Aerosolized pentamidine.
  • Topical antifungals.
  • TMP / SMX.
  • AZT.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Significant hepatic disease including HBsAg or hepatitis C positivity.
  • Significant neurologic disease such as loss of intellectual ability, motor deficits, or seizure disorder.
  • Significant cardiac disease including dysrhythmia or cardiomyopathy.
  • Significant medical condition or laboratory abnormality that may pose additional risk to patient on study or confound the results.
  • Has a social situation that may interfere with study participation.

Concurrent Medication:


  • Oral contraceptives.

Patients with the following prior conditions are excluded:

  • History of serious allergic drug reactions.
  • History of significant cardiac disease.
  • Participation on another clinical trial within the past 4 weeks.
  • Donated blood within the past 4 weeks.

Prior Medication:

Excluded within the past 4 weeks:

  • Hematopoietic growth factors.

Excluded within the past 2 weeks:

  • Antiretroviral agent other than zidovudine.
  • Oral contraceptives.
  • Prophylaxis for opportunistic infections, other than aerosolized pentamidine, topical antifungals, and TMP/SMX.
  • Any other medication unless approved by Merck clinical monitor. Current illicit drug use.
Sexes Eligible for Study: All
10 Years to 18 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
NIH AIDS Clinical Trials Information Service
October 1995

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP